Title:
細胞増殖異常に伴う疾患に関連するポリペプチド抗原の同定方法及びそのような疾患の治療に有効な組成物
Document Type and Number:
Japanese Patent JP5224632
Kind Code:
B2
Abstract:
Methods and compositions for the development of effective cancer therapies using mitotic inhibitors which have limited general toxicity to normal, non-cancerous cells and tissues are provided. The methods and compositions utilize cytotoxic compounds comprised of a cell-binding agent (e.g., antibodies) conjugated to an anti-mitotic compound (e.g., maytansinoids). The invention further provides antibodies which are substantially incapable of inducing antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC), thereby ensuring that the therapeutic effect is mediated primarily by the anti-mitotic component of the cytotoxic compound, rather than by indirect cell killing via ADCC and/or CDC. The antibodies of the invention further are capable of differentiating between polypeptide antigens which are more highly expressed on proliferating cancer cells as compared to proliferating non-cancer cells.
Inventors:
Levinson, Arthur Dee.
Application Number:
JP2003525613A
Publication Date:
July 03, 2013
Filing Date:
September 04, 2002
Export Citation:
Assignee:
Genentech, Incorporated
International Classes:
G01N33/53; A61K39/395; A61P35/00; C07K16/30; C12P21/08; C12Q1/02; C12Q1/68; G01N33/574; G01N33/577; G01N33/68
Foreign References:
| WO2001055720A2 |
Other References:
Ravi V.J.Chari et al.,CANCER RECEARCH, vol.52,1992,pp.127-131
Attorney, Agent or Firm:
Sonoda Yoshitaka
Kobayashi Yoshinori
Kobayashi Yoshinori